Introduction
This chapter contains analyses of adult patients starting renal replacement therapy (RRT) in the UK in 2015. The methodology and results for these analyses are in four separate sections: geographical variations in incidence rates; the demographic and clinical characteristics of patients starting RRT; analyses of late presentation and delayed referral; and new for this report, acute haemodialysis sessions.
The data were analysed using SAS 9.3.
Definitions
The definition of incident patients is given in detail in appendix B: Definitions and Analysis Criteria (www. renalreg.org). In brief, it is all patients over 18 who commenced RRT in the UK in 2015 and who did not recover renal function within 90 days. Note that this does not include those with a failed renal transplant who returned to dialysis.
Differences may be seen in the 2010 to 2014 numbers now quoted when compared with previous publications because of retrospective updating of data in collaboration with renal centres. Also, for patients who were initially thought to have acute renal failure, subsequent chronic RRT codes may have been received in the following year's data, allowing the UK Renal Registrty (UKRR) to backdate the start date of RRT.
Where applicable and possible, pre-emptive transplant patients were allocated to their work up centre rather than their transplant centre. However, this was not possible for all such patients and consequently some patients probably remain incorrectly allocated to the transplanting centre. The term established renal failure (ERF) as used within this chapter is synonymous with the terms end stage renal failure/disease (ESRF or ESRD).
UK Renal Registry coverage
The UKRR received individual patient level data from 70 adult renal centres in the UK (five centres in Wales, five in Northern Ireland, nine in Scotland, 51 in England). Cambridge renal centre (Addenbrooke's) was unable to submit 2015 data at patient level prior to the UKRR closing the database and only provided summary numbers of patients starting RRT by treatment modality. This centre is therefore excluded from most analyses in this chapter. Data from centres in Scotland were obtained from the Scottish Renal Registry. Data on children and young adults can be found in chapter 4: Demography of the UK Paediatric Renal Replacement Therapy population in 2015. Table 1 .1 lists the relevant items from the Renal Association Guidelines on the Planning, Initiating and Withdrawal of Renal Replacement Therapy [1] . Many of the audit measures are not currently reported by the UKRR; mainly due to a high proportion of incompleteIntroduction Over the years there have been wide variations in incidence rates between renal centres. Equity of access to RRT is an important aim but hard to assess as the need for RRT depends on many variables including medical, social and demographic factors such as underlying conditions, age, gender, social deprivation and ethnicity. Thus, comparison of crude incidence rates by geographical area can be misleading. This year's report again uses age and gender standardisation of Clinical Commissioning Group/Health Board (CCG/HB) rates as well as showing crude rates. It also gives the ethnic minority percentage for each area as this influences incidence rates.
Renal Association Guidelines

Methods
CCG/HB level
Crude incidence rates per million population (pmp) and age/ gender standardised incidence ratios were calculated as detailed in appendix D: Methodology used for Analyses (www.renalreg. org).
For the calculation of rates and standardised ratios by CCG/ HB, for which patient-level information is needed for age/gender standardisation, the Cambridge data from 2014 were used in place of the missing 2015 data. This is obviously a gross approximation but was felt to be a better approach than excluding a number of CCGs from the analyses. As the main analysis is based on six years of data the effect of this approximation will be not as great as it would be for a one year analysis. Those CCGs that were at least in part (.10%) covered by Cambridge were identified using 2010-14 data and flagged in table 1.3. For three CCGs with between 10% and 65% of the RRT starters being incident patients of Cambridge, rates/ratios for 2015 are shown but the values are flagged. For CCGs where most patients (.65%) are thought to be incident patients of Cambridge, the 12 Nephron 2017;137(suppl1): Gilg/Methven/Casula/Castledine 2015 rates/ratios have been blanked as they are based in large part on 2014 data.
For Sheffield, 55 of their 151 incident patients for 2015 were not submitted. Here the data were used as received but the relevant CCGs are again flagged/blanked as above as their rates/ratios will be underestimates.
Centre level
As mentioned previously, Cambridge was unable to submit 2015 data at patient level but provided the UKRR with information allowing their incident number for 2015 to be estimated and this estimate has been used in tables 1.2 and 1.4 but not elsewhere in this chapter. A number of other centres have informed the UKRR of corrections to the data they submitted and these have been applied to tables 1.2 and 1.4 but not elsewhere in this chapter. These are detailed in the footnotes to table 1.4. The largest of these was Sheffield with approximately a third of the 2015 incident patients not submitted. Therefore the results for Sheffield are likely not representative. In particular, all those submitted were early presenters (see the third section of this chapter).
For the methodology used to estimate catchment populations see appendix E: Methodology for Estimating Catchment Populations (www.renalreg.org).
Results
Overall
In 2015, the number of adult patients starting RRT in the UK was 7,814 equating to an incidence rate of 120 pmp (table 1. 2), compared with 115 pmp in 2014. Wales remained the country with the highest incidence rate (126 pmp -figure 1.1). There continued to be very marked gender differences in incidence rates which were 152 pmp (95% CI 148-156) in males and 89 pmp (95% CI 86-92) in females.
The denominators used for these rates were the entire population i.e. they include under 18 year olds. When incident patients aged under 18 were included in the numerator the UK rate was 122 pmp.
CCG/HB level Table 1 .3 shows incidence rates and standardised incidence ratios for CCG/HBs. There were wide variations between areas. From the analysis using all six years, out of a total of 235 areas, 48 areas had notably high ratios and 71 notably low. The standardised incidence ratios ranged from 0.63 to 2.64 (IQR 0.82, 1.10). The crude rates ranged from 71 pmp to 205 pmp (IQR 93 pmp, 117 pmp). As previously reported, urban areas with high percentages of non-White residents tended to have high incidence rates. Figure 1 .2 shows the strong positive correlation between the standardised incidence ratio and the percentage of the CCG/HB population that was nonWhite.
Centre level
The number of new patients starting RRT at each renal centre from 2010 to 2015 is shown in table 1.4. The table also shows centre level incidence rates (per million population) for 2015. For most centres there was a lot of variability in the numbers of incident patients from one year to the next making it hard to see any underlying trend. Some centres have had an increase in new patients over time and others have fallen. The variation may reflect chance fluctuation, the introduction of new centres, changes in catchment populations or in completeness of reporting. Variation over time may also be due to changing incidence of established renal failure (increases in underlying disease prevalence, survival from comorbid conditions and recognition of ERF), changes to treatment thresholds such as a greater emphasis on pre-emptive transplantation or the introduction of conservative care programmes. Analysis of CKD stage 5 patients not yet on RRT is required to explore some of these underlying mechanisms for centre level incidence rate changes.
There was an increase of 18.8% in new patients for England between 2010 and 2015. Across all four countries the change between 2010 and 2015 was an increase of 18.2%.
Demographics and clinical characteristics of patients starting RRT
Methods
Age, gender, primary renal disease, ethnic origin and treatment modality were examined for patients starting RRT. A mixture of old and new (2012) ERA-EDTA codes for primary diagnoses [2] were received from centres. The split was about 30 : 70 for 2015 incident patients. For those people without an old code, new The number starting RRT, and hence the RRT incidence rate, published in the Scottish Renal Registry report for the same period is slightly lower at 619 (115 pmp). This is explained by differences in the definition of incident RRT patients between the two registries
Rate per million population Gilg/Methven/Casula/Castledine Gilg/Methven/Casula/Castledine Gilg/Methven/Casula/Castledine codes (where available) were mapped back to old codes using the mapping available on the ERA-EDTA website. As recommended in the notes for users in the ERA-EDTA's PRD code list document, this mapping is provided for guidance only and has not been validated; therefore care must be taken not to over interpret data from this mapping. These codes were grouped into the same eight categories as in previous reports, the details are given in appendix H: Ethnicity and ERA-EDTA Coding (www.renalreg.org). Most centres electronically upload ethnicity coding to their renal information technology (IT) system from the hospital Patient Administration System (PAS). Ethnicity coding in these PAS systems is based on self-reported ethnicity. For the remaining centres, ethnicity coding is performed by clinical staff and recorded directly into the renal IT system (using a variety of coding systems). Data on ethnic origin were grouped into White, South Asian, Black, Chinese or Other. The details of regrouping of the PAS codes into the above ethnic categories are provided in appendix H: Ethnicity and ERA-EDTA Coding (www.renalreg.org). Chi-squared, Fisher's exact, ANOVA and Kruskal Wallis tests were used as appropriate. Estimated glomerular filtration rate (eGFR) at the start of RRT was studied amongst patients with eGFR data within 14 days before the start of RRT. The eGFR was calculated using the abbreviated 4 variable MDRD study equation [3] . For the purpose of the eGFR calculation, patients who had missing ethnicity but a valid serum creatinine measurement were classed as White. The eGFR values were log transformed due to their skewed distribution.
Results
Incidence rates had plateaued in the nine years before the previous report but they increased in 2014 and again in 2015 ( figure 1.3) . Figure 1 .4 shows RRT incidence rates for 2015 by age group and gender. For both men and women, the peak rate was in the 75-79 age group. Showing numbers starting RRT (rather than rates); figure 1.5 shows that the 65-74 age group contained the most incident patients for HD and the 55-64 age group included the most people for PD.
Age
In 2015, the median age of patients starting renal replacement therapy was 64.4 years (table 1.5) and this has changed little over recent years. Per modality, the median age at start was 66.9 years for patients starting on HD, 60.3 for patients starting on PD and 50.8 for There were large differences between centres in the median age of incident patients (figure 1.6) reflecting differences in the age and ethnic structure of the catchment populations and also, particularly in smaller centres, chance fluctuations. The median age of patients starting treatment at transplant centres was 62. There has been recent interest in the access of older patients to RRT and this is explored again this year. Averaged over 2010-2015, crude CCG/HB incidence rates in the over 75 years age group varied from 57 per million age related population (pmarp) in Borders to 1,059 pmarp in NHS Brent (IQR 252 pmarp, 399 pmarp). The wide range of treatment rates suggests that there was geographical variation in the prevalence of comorbid and predisposing renal conditions as well as uncertainty within the renal community about the suitability of older patients for dialysis. The variation between CCG/HBs seen in the over 75s was much greater than the variation seen in the overall analysis although some of this difference is likely to be due to the smaller numbers included in the over 75 analysis. 
Gender
More men than women started RRT in every age group except the youngest ( figure 1.7) . The overall breakdown was 62.2% male, 37.8% female equating to a M : F ratio of 1.65.
Ethnicity
As in previous reports, Scotland is not included in this section as completeness of ethnicity data was low. Across centres in England, Wales and Northern Ireland the average completeness was 95.8% for 2015 incident patientssimilar to the 94.8% seen last year. A five year cohort was used for the centre level analysis presented here (table 1.7a). For completeness data by centre for 2015 incident patients see the Introduction chapter of this report. Table 1 .7b shows the overall detailed ethnicity breakdown for England for 2015.
Primary renal diagnosis
The breakdown of primary renal diagnosis (PRD) by centre is shown for a 2011-2015 incident cohort in table 1.8a. The breakdown by country is shown for 2015 incident patients in table 1.8b. For completeness data for 2015 by centre see the Introduction chapter of this report. Fifty-seven centres provided data on over 90% of incident patients and 28 of these centres had 100% completeness. There was only a small amount of missing data for Wales and Scotland, whilst Northern Ireland had 9.5% missing and England had 11.3% missing. The overall percentage missing was 9.7% and this was slightly lower in the under compared to the over 65 year olds (8.8% and 10.8% respectively). Seven centres had missing PRD for more than 25% of incident patients.
The UKRR continues to be concerned about centres with apparently very high data completeness for PRD but also very high rates of 'uncertain' diagnoses (EDTA code 00: Chronic renal failure; aetiology uncertain). It is accepted that there will inevitably be a number of patients with uncertain aetiology and that the proportion of these patients will vary between clinicians and centres as the definitions of e.g. renal vascular disease and hypertensive renal disease remain relatively subjective. Many of the new ERA-EDTA PRD codes allow clinicians to indicate the basis for the diagnosis of the renal disease (e.g. based on histology or not). Adoption of these new codes should therefore reduce the coding of PRD as uncertain. This year there was again a lot of variability between centres but no centre had a far higher percentage with 'uncertain' diagnosis than the others. Last year there were three centres with diagnosis 'uncertain' for over 45% of their incident patients -Cambridge (65%), Colchester (61%) and Ipswich (79%). The situation has improved this year for Colchester but Ipswich now has 65% missing data and Cambridge were unable to supply the data.
There was a lot of variability between centres in the percentages with the specific diagnoses (partly due to the reasons mentioned above). For example, for the 2011-2015 cohort, the percentage with diabetes as PRD varied from 15% to 40%.
The overall UK distribution of PRDs is shown in table 1.9. When using a simple under versus over 65 22  374  7  21  17  17  20  8  8  2  M RI  9  819  10  28  13  14  19  7  6  3  Middlbr  1  561  19  26  12  5  18  8  6  6  Newc  1  521  14  21  15  4  23  9  7  8  Norwch  4  409  26  20  15  3  15  8  6  6  Nottm  1  560  20  23  12  5  20  8  8  6  Oxford  0  897  15  28  16  6  15  9  6  5  Plymth  10  258  10  19  21  7  12  8  8  15  Ports  11  865  10  25  14  9  19  9  8  7  Prestn  0  759  14  24  14  11  15  7  9  6  Redng  1  477  17  29  13  3  18  5  7  7  Salford  42  394  Sheff  1  667  18  25  18  5  10  8  8  8  Shrew  4  297  23  24  8  5  25  5  4  6  Stevng  8  609  17  24  11  2  32  7  3  4  Sthend  0  162  19  19  15  4  20  10  7  7  Stoke  11  438  10  27  11  8  22  8  5  8  Sund  2  299  4  24  13  19  18  8  7  8  Truro  2  248  11  24  20  8  17  5  8  8  Wirral  22  223  8  28  8  15  26  7  3  5  Wolve  1  411  25  20  13  2  26  4  5  4  York  1  268  7  19  18  9  22  10  9  7 26 Nephron 2017;137(suppl1): Gilg/Methven/Casula/Castledine split (data not shown) diabetic nephropathy was the most common renal diagnosis in both the under and over 65 year age groups, accounting for 28% of all (non-missing) incident diagnoses. Glomerulonephritis and autosomal dominant polycystic kidney disease (ADPKD) made up much higher proportions of the younger than the older incident cohorts (18% vs 10% and 11% vs 4% respectively), whilst patients with renal vascular disease comprised a much higher percentage of the older rather than the younger patients (10% vs 2%). Uncertainty about the underlying diagnosis was also much more likely in the older rather than the younger cohort (18% vs 11%). For all primary renal diagnoses except ADPKD, the male to female ratio was 1.4 or greater. This gender difference may relate to factors such as smoking, hypertension, atheroma and renal vascular disease, which are more common in males and may influence the rate of progression of renal failure. Table 1 .10 shows the incidence rates for each PRD per million population for the 2015 cohort. As there were some missing data, the rates for at least some of the diagnoses will be underestimates.
First established treatment modality
In 2015, the first treatment recorded, irrespective of any later change, was haemodialysis in 73.1% of patients, peritoneal dialysis in 19.2% and pre-emptive transplant in 7.7% (table 1.11). The percentage having a pre-emptive transplant fell in 2015, however, about half of this drop is due to Cambridge (a transplant centre) not being included in the data for 2015. Many patients undergo a brief period of HD before switches to other modalities are, or can be, considered. Therefore, the established modality at 90 days is more representative of the elective first modality and this modality was used for the remainder of this section. For these analyses, the incident cohort from 1st October 2014 to 30th September 2015 was used so that follow up to 90 days was possible for all patients. By 90 days, 5.2% of incident patients had died and a further 0.5% had stopped treatment, leaving 94.3% of the original cohort still on RRT. Table 1 .12a shows the percentages on each treatment modality at 90 days both as percentages of all of those starting RRT and then of those still on treatment at 90 days. Expressed as percentages of the whole incident cohort, 67.3% were on HD at 90 days, 18.4% were on PD and 8.6% had received a transplant. Expressed as percentages of those still receiving RRT at 90 days, 71.3% were on HD, 19.6% on PD and 9.1% had received a transplant. Figure 1 .8 shows the modality breakdown with the HD patients further subdivided. Of those still on RRT at 90 days, 41% were treated with hospital HD, 30% with satellite HD, and only 0.4% were receiving home HD at this early stage. This 0.4% on home HD was 27 patients (across 11 centres). This was a decrease from the 0.6% (43 patients across 16 centres) seen for 2014. Chapter 2: UK Renal Replacement Therapy Prevalence in 2015 shows that 4.2% of all dialysis patients were receiving home HD. Table 1 .12b shows the treatment breakdown at 90 days by centre. Here a five year cohort was used (1st October 2010 to 30th September 2015). The percentage of incident patients who had died by 90 days varied considerably between centres. The ongoing observation that in some centres few patients die by 90 days is difficult to explain clinically. Differences in the definition of whether patients have acute or chronic renal failure and when they then report patients to the UKRR (with a period of time between start of RRT and reporting to the UKRR in which they have by definition survivedimmortal time bias) may be a factor in this apparent variation along with possible differences in clinical practice.
Using just 2015 incident patients, the percentage of patients still on RRT at 90 days who had a functioning transplant at 90 days varied between centres from 0% to 35% (between 7% and 35% for transplanting centres and between 0% and 13% for non-transplanting centres). The mean percentage of the incident cohort with a functioning transplant at 90 days was greater in transplanting compared to non-transplanting centres (11.9% vs 5.8%). One possible reason could be that some patients transplanted pre-emptively were attributed to the incident cohort of the transplanting centre rather than that of the referring centre. Table 1 .13 gives the HD/PD breakdown by age group for those incident patients on dialysis at 90 days (incident cohort 1/10/2012 to 30/09/2015). The percentage on PD at 90 days was about 50% higher in patients aged under 65 years than in older patients (27% vs 17%). In both age groups there was a lot of variability between centres in the percentage on PD. In 2015, the median age at start for those on HD at 90 days was 66.7 years compared with 59.9 years for PD. There were eleven centres where the percentage of patients treated with PD was the same as or higher in the over 65s than the under 65s (seven centres for the three year cohort shown in table 1.13) . This reflects the use of assisted PD programmes -a feature of note and one that is valued by the patients and their families.
Modality change over time Table 1 .14 gives the breakdown of status/treatment modality at four subsequent time points by initial treatment type for patients starting RRT in 2010. Fifty-four percent of patients who started on HD had died within five years of starting. This compared to 34% and 4% for those starting on PD or transplant respectively. Of the patients starting on PD, 90% were on PD at 90 days but this percentage dropped sharply at the later time points. In contrast, 92% of patients starting with a transplant were also transplant patients at the five year time point. Renal function at the time of starting RRT
The mean eGFR at initiation of RRT in 2015 was 8.5ml/min/1.73 m 2 . This is shown by age group in figure 1.9 . Figure 1 .10 shows serial data from centres reporting to the UKRR every year since 2006. For the six years before 2011 there was higher average eGFR at start of RRT for PD than HD patients but on average, the values were more similar between treatments for 2011 to 2015.
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Introduction
Late presentation to a nephrologist is regarded as a negative aspect in renal care. It can be defined in a number of ways as it has a range of possible causes. There are many patients with chronic kidney disease who are regularly monitored in primary or secondary care and whose referral to nephrology services is delayed (delayed or late referral). In contrast, other patients present late to medical services due to no particular deficiency in the service; those with either such slowly progressive disease as to have remained asymptomatic for many years or the opposite -those with rapidly progressive CKD. The main analyses presented here do not differentiate between these groups and include any patient first seen by renal services within 90 days of starting RRT as 'late presentation'. One analysis attempts to capture 'late referrals': it shows the percentage presenting 
Methods
Date first seen by a nephrologist has not been collected from the Scottish Renal Registry and so Scottish centres were excluded from these analyses. Data were included for incident patients in English, Welsh or Northern Irish centres in the years 2014 to 2015. This two year cohort was used for most of the analyses in order to make the late presentation percentages more reliably estimated and to allow these to be shown for subgroups of patients. The date first seen in a renal centre and the date of starting RRT were used to define the late presenting cohort. A small amount of data was excluded because of actual or potential inconsistencies. Only data from those centres with 75% or more completeness for the relevant year were used. Data were excluded if 10% or more of the patients were reported to have started RRT on the same date as the first presentation. This was because investigation has shown that this is likely due to misunderstanding on the part of the renal centres resulting in incorrect recording of data. Sheffield was excluded from the late presentation analyses because 55 of their incident patients for 2015 were not submitted to the UKRR and those 96 that were submitted were all early presenters. After these exclusions, data on 10,038 patients were available for analysis. Presentation times of 90 days or more before start were defined Gilg/Methven/Casula/Castledine as early presentation and times of less than 90 days were defined as late presentation. Estimated glomerular filtration rate (eGFR) at the start of RRT was studied amongst patients with eGFR data within 14 days before the start of RRT. The eGFR was calculated using the abbreviated 4 variable MDRD study equation [3] . For the purpose of the eGFR calculation, patients who had missing ethnicity but a valid serum creatinine measurement were classed as White. The eGFR values were log transformed due to their skewed distribution.
A mixture of old and new (2012) EDTA codes for primary diagnoses were received from centres. New codes were received for about 64% of 2014 incident patients and for about 70% of 2015 incident patients. For those people without an old code, new codes (where available) were mapped back to old codes. These codes were grouped into the same eight categories as in previous reports, the details are given in appendix H: Ethnicity and ERA-EDTA Coding (www.renalreg.org).
The 'acute' group was made up of those people with conditions likely to present with rapidly deteriorating renal function: crescentic (extracapillary) glomerulonephritis (type I, II, III), nephropathy (interstitial) due to cis-platinum, renal vascular disease due to malignant hypertension, renal vascular disease due to polyarteritis, Wegener's granulomatosis, cryoglobulinemic glomerulonephritis, myelomatosis/light chain deposit disease, Goodpasture's syndrome, systemic sclerosis (scleroderma), haemolytic ureaemic syndrome, multi-system disease -other, tubular necrosis (irreversible) or cortical necrosis, Balkan nephropathy, kidney tumour(s), and traumatic or surgical loss of kidney(s). Late presentation by centre Figure 1 .11 shows that late presentation varied between centres from 5% to 35% in patients starting RRT in 2014 to 2015. The overall rate of late presentation was 17.0% and was 12.2% once those people with diseases likely to present acutely were excluded. Table 1 .16 shows the overall percentage presenting late for the combined 2014/2015 incident cohort, the percentages presenting late amongst those patients defined as not having an 'acute diagnosis' and the percentages amongst nondiabetics (as PRD).
Results
Data completeness
Considerable differences exist between centres in late presentation rates. One centre (Birmingham Heartlands) attained a late presentation rate of just over 5%. Four centres (Ipswich, Southend, Stoke and Wirral) reported that over 40% of their incident patients were only seen within a year of commencement of RRT. These differences have implications for their regions and referral pathways.
Late presentation in 2015 and the trend over time
There has been a steady decline nationally in the proportion of patients presenting late to renal services, with some centres achieving ,10% late presentation rates. This may be a consequence of the National CKD guidelines published by the Medical and GP Royal Colleges [6] , the Quality and Outcomes Framework (QOF) initiative (www.dh.gov.uk) raising awareness of CKD amongst non-nephrologists and the introduction of estimated GFR reporting. The Health Foundation is currently funding a quality improvement initiative rolling out a computer program that flags people with declining kidney function to laboratory staff who in turn flag these people to the GP to ensure they are aware of the decline and have considered referral to a nephrologist. About twenty renal centres are participating in this initiative (ASSIST-CKD [7] ) which is being managed through Kidney Research UK, the UKRR is leading the stepped-wedge evaluation to establish effectiveness. In 2015, 71.3% of incident patients presented to nephrology services over a year before they started RRT, an increase from the 69.4% reported last year. The remaining patients presented within a year of start, with 8.1% of patients presenting within the 6-12 month window before RRT, 4.2% within 3-6 months and 16.4% within three months of RRT start. Figure 1 .12 shows this breakdown by year for those 33 centres supplying data over 75% complete for each of the last six years. The figure shows an increase over time in the percentage of patients presenting a year or more before starting RRT. As shown in previous reports this increase was even more marked in the years before those shown in the figure. In 2005, only 52.6% of incident patients presented over a year before they started RRT.
Characteristics of patients presenting late versus those presenting early
In the combined 2014/2015 incident cohort, the median age was a little lower in those presenting late than those presenting early (table 1.17). The male : female ratio was higher in the group presenting late than those presenting early. There were large differences in the The finding of lower average eGFR in those presenting late is in contrast to some of the studies in the literature but many of those studies pre-date the era of routine use of eGFR [8, 9] . A recent Cochrane review [10] has shown that eGFR was indeed lower in RRT patients referred late (mean difference of 0.42 ml/min/1.73 m 2 ) compared to those presenting early (definition: more than six months before starting RRT) consistent with UKRR data.
In the 2014/2015 cohort, the percentage of South Asian and Black patients presenting late (,90 days) was lower than in Whites (14.0% vs 17.3%: p , 0.001). Above age 45, the median duration of pre-RRT care did not vary greatly with age group (figure 1.13).
Primary renal disease and late presentation
In the 2014/2015 cohort, there were large differences in late presentation rates between primary renal diagnoses (Chi-squared test p , 0.0001) (table 1.18). Patients in the acute group or with data not available had high rates of late presentation as anticipated. Those with diabetes and adult polycystic kidney disease or pyelonephritis had low rates in keeping with their longer natural histories of CKD progression. There was a notable decline in the proportion of diabetics presenting late up until 2007. Since then the proportion has been stable. The decline seen earlier likely reflects national initiatives to screen patients with diabetes for proteinuria and falling GFR.
Comorbidity and late presentation
In the 2014/2015 cohort, the percentage of patients who were recorded as having no comorbidity was similar in those who presented late as in those presenting earlier (49.1% vs 51.1%: p = 0.2). That said however, there were differences in those with comorbidities: cardiovascular disease was less common and liver disease and malignancy more common in those presenting late compared to those presenting early (table 1.19) perhaps reflecting underlying causes of CKD and its progression. This is in keeping with findings from other studies [8] [9] 11] . Gilg/Methven/Casula/Castledine International comparisons Figure 1 .14 shows the crude RRT incidence rates (including children) for 2014 for various countries. The non-UK data are from the USRDS [12] ; 2014 was the latest year available at time of writing. The UK incidence rate was similar to those in many other Northern European countries, Australia and New Zealand but remained markedly lower than in some other countries, most notably Greece, Japan and the USA. There are numerous reasons for these differences which have been documented and explored in other ecological studies and summarised by this review [13] . 
Discussion
Across the UK, as a whole, the renal replacement therapy (RRT) incidence rate for 2015 was higher than for 2014, 2013 and 2012. Partly because of the smaller numbers involved, rates have been more variable over the last few years for Northern Ireland, Scotland and Wales compared with England. Wales continued to have the highest incidence rate and there remained large between centre variation in incidence rates for RRT some of which is likely explained by population differences in ethnicity and age structure. There was a lot of variation between CCG/HBs in the rates of older people (.75) starting RRT and also substantial between centre variation in use of different types of RRT modality some of which suggests inefficient use of cheaper and more effective forms of treatment. Although large numbers of patients continued to present late to renal centres this proportion has dropped substantially in the last decade. Some centres' lower rates (,10%) suggest that local factors may be worth exploring with the aim of improving this aspect of renal care and one example of this is the ASSIST-CKD Study being funded by the Health Foundation. More frequent and more detailed data downloads and prospectively capturing data on patients attending renal centres from eGFR 30 ml/min/ 1.73 m 2 will hopefully allow the UKRR to explore these areas of variation in advanced CKD care.
Introduction
The analyses presented here relate to data submitted to the UKRR about individual haemodialysis sessions, performed for acute kidney injury (AKI). These haemodialysis session data were submitted by centres for the first time on treatment undertaken during 2015. Non-UK data from USRDS [12] UK Renal Replacement Therapy Incidence in 2015
Nephron 2017;137(suppl1): Methods Correct use of acute and chronic timeline codes Patients who have acute HD sessions and do not recover renal function, becoming established on dialysis, should have two separate entries in their treatment timeline; the first, a modality code on the date of the first dialysis session; acute haemodialysis or acute peritoneal dialysis (timeline entries 81-83), the second, a chronic dialysis code, on the date it was decided that the person had ERF; for HD or PD (timeline codes 1-19 can be used to describe the appropriate form of HD or PD being provided). When the decision is made that the person has ERF, the timeline should NOT be backdated to the original date of first treatment (as was advised prior to 2009). The resultant date is the same for some purposes (such as incidence) as backdating is undertaken at the UKRR when defining the start date of incident patients (see appendix B: Definitions and Analysis Criteria (www. renalreg.org)). The advantage of the backdating procedure being undertaken by the UKRR rather than by the centres themselves is that the most granular information is provided by the acute timeline codes and can be used for other analyses such as those on acute HD sessions presented here.
Definition of an acute HD session Session data were submitted on HD sessions for AKI, ERF and plasma exchange (PEX). A 'session type' variable was used to identify and exclude PEX sessions but the individual HD sessions were not labelled in the dataset as being acute or chronic, so the timeline was used to identify if an HD session was undertaken for AKI or ERF, using the following logic (applied in this order); i) If a timeline entry for AKI was submitted and the HD session dates were within the period defined as AKI by the timeline dates, then the session was defined as acute. ii) If there was a timeline entry of ERF before the date a HD session occurred then the session was defined as chronic. iii) If there was a timeline entry for ERF, and no prior timeline entry of acute dialysis, but the dates of the HD sessions preceded the stated date for chronic HD, then the HD sessions were defined as acute. There is potential for misclassification error here due to the assumption being made (that there is a missing acute timeline code, rather than that the date of starting chronic RRT was wrong).
Completeness and other data issues
If multiple HD sessions were recorded as occurring within a six hour period, only the first session was included in the analysis on the assumption that these additional HD sessions were duplicates or a result of technical problems, for example problems with an HD machine, and that they only represented one treatment.
HD session data were submitted to the UKRR for the first time for treatments undertaken in 2015, and there were some early issues with missing data. In the first quarter of 2015, a significant proportion of the 'session type' variable was missing, so HD sessions could not be reliably differentiated from PEX sessions (after this it was 100% complete). In addition, data submission began at staggered time-points over the first half of 2015. Therefore only session data from July-December 2015 have been included in this analysis.
The submission of data regarding HD sessions has been mandated by NHS England. Submission of these data from renal centres in Northern Ireland and Wales is optional. The Scottish Renal Registry does not collect these data.
Results
Forty of the 52 adult renal centres in England submitted individual HD session data. Of these, London Guys and Manchester Royal Infirmary submitted only HD session data pertaining to chronic HD sessions (according to the logic described in the methods section to identify acute sessions). All five Northern Ireland renal centres submitted data regarding acute and chronic sessions. In Wales, four centres (all except Clwyd) submitted HD sessions data, but only Swansea submitted data on acute HD sessions.
From the HD sessions data supplied by these 49 renal centres, our algorithm defined sessions as acute HD sessions for 998 patients. Of these, 929 were defined using step i) of the algorithm, i.e. using timeline entries of acute dialysis. The remaining 69 patients had sessions defined as acute HD sessions despite having no acute timeline entries (these are the cases where the third step of the algorithm defined in the methods section was used). See table 1.20.
From these same 49 centres, there were 1,038 people who, according to the timeline, had a spell of acute dialysis that included a period during July to December 2015. Of these, 929 people had HD sessions data supplied which were defined as acute sessions by our algorithm. The remaining 109 people had no HD session data supplied for the time period that they were on acute dialysis according to the timeline. (Some of these people had no HD sessions data supplied at all and others had some sessions supplied but only for after the time period when the timeline defined them as acute patients). Table 1 .21 shows the number of individual HD sessions reported to the UKRR, and what proportion were defined as acute sessions by our algorithm.
Data completeness of variables associated with haemodialysis sessions
